论文部分内容阅读
心房颤动是缺血性脑卒中的重要独立危险因素,抗凝治疗是预防非瓣膜性心房颤动(NVAF)患者缺血性卒中的有效方法。传统抗凝药物华法林疗效肯定但使用不便。直接凝血酶抑制剂及Ⅹa因子抑制剂干扰凝血过程,抗凝作用肯定,具有剂量固定、无需监测凝血指标的优点,受到临床重视。本文对此类新型抗凝药物的药理作用、药代动力学及临床评价等做一综述。
Atrial fibrillation is an important independent risk factor for ischemic stroke. Anticoagulation therapy is an effective method to prevent ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF). Traditional anticoagulant warfarin effect is affirmative but inconvenient to use. Direct thrombin inhibitors and factor Xa inhibitors interfere with the process of coagulation, anticoagulant effect with a fixed dose, without the need to monitor the advantages of coagulation indicators, clinically important. This article reviews the pharmacological effects, pharmacokinetics and clinical evaluation of these new anticoagulants.